Late Recurrence and Progression in Non-muscle-invasive Bladder Cancers After 5-year Tumor-free Periods

Kazuhiro Matsumoto, Eiji Kikuchi, Yutaka Horiguchi, Nobuyuki Tanaka, Akira Miyajima, Ken Nakagawa, Jun Nakashima, Mototsugu Oya

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: To evaluate the recurrence and progression in patients with non-muscle-invasive bladder tumors who remained tumor-free for at least 5 years, which should assist in the development of schedules of their follow-up evaluations. Non-muscle-invasive bladder tumors that recur or progress at a late time point are not rare. Methods: Between 1985 and 2002, 814 cases diagnosed with non-muscle-invasive bladder cancer were treated with transurethral resection. Of these 814 cases, 262 patients with no tumor recurrence for more than 5 years were included in the study. The median follow-up interval was 10.0 years. Results: During the follow-up period, 39 tumors (14.9%) showed tumor recurrence. The 5- and 10-year recurrence-free survival rates were 81.6% and 76.0%, respectively. There was no significant difference in tumor recurrence among the low-, intermediate-, and high-risk groups based on the current clinical guideline. Only the use of intravesical mitomycin C was determined to be a significant unfavorable risk factor for late recurrence. Five patients (1.9%) experienced stage progression, 3 of whom did not have metastases at the time of diagnosis of the progression but died because of bladder cancer disease. Conclusions: After a 5-year tumor-free period, even in the low-risk group, recurrence occurred at a late time point to a degree that was the same as that for the intermediate- and high-risk groups. Finally, some of the high-risk patients experienced late progression with a high degree of malignant behavior, suggesting longer follow-up is needed for each patient.

Original languageEnglish
Pages (from-to)1385-1390
Number of pages6
JournalUrology
Volume75
Issue number6
DOIs
Publication statusPublished - 2010 Jun

Fingerprint

Urinary Bladder Neoplasms
Recurrence
Neoplasms
Urinary Bladder Diseases
Mitomycin
Appointments and Schedules
Survival Rate
Guidelines
Neoplasm Metastasis

ASJC Scopus subject areas

  • Urology

Cite this

Late Recurrence and Progression in Non-muscle-invasive Bladder Cancers After 5-year Tumor-free Periods. / Matsumoto, Kazuhiro; Kikuchi, Eiji; Horiguchi, Yutaka; Tanaka, Nobuyuki; Miyajima, Akira; Nakagawa, Ken; Nakashima, Jun; Oya, Mototsugu.

In: Urology, Vol. 75, No. 6, 06.2010, p. 1385-1390.

Research output: Contribution to journalArticle

Matsumoto, Kazuhiro ; Kikuchi, Eiji ; Horiguchi, Yutaka ; Tanaka, Nobuyuki ; Miyajima, Akira ; Nakagawa, Ken ; Nakashima, Jun ; Oya, Mototsugu. / Late Recurrence and Progression in Non-muscle-invasive Bladder Cancers After 5-year Tumor-free Periods. In: Urology. 2010 ; Vol. 75, No. 6. pp. 1385-1390.
@article{176b03d54703490daf0828083875d0aa,
title = "Late Recurrence and Progression in Non-muscle-invasive Bladder Cancers After 5-year Tumor-free Periods",
abstract = "Objectives: To evaluate the recurrence and progression in patients with non-muscle-invasive bladder tumors who remained tumor-free for at least 5 years, which should assist in the development of schedules of their follow-up evaluations. Non-muscle-invasive bladder tumors that recur or progress at a late time point are not rare. Methods: Between 1985 and 2002, 814 cases diagnosed with non-muscle-invasive bladder cancer were treated with transurethral resection. Of these 814 cases, 262 patients with no tumor recurrence for more than 5 years were included in the study. The median follow-up interval was 10.0 years. Results: During the follow-up period, 39 tumors (14.9{\%}) showed tumor recurrence. The 5- and 10-year recurrence-free survival rates were 81.6{\%} and 76.0{\%}, respectively. There was no significant difference in tumor recurrence among the low-, intermediate-, and high-risk groups based on the current clinical guideline. Only the use of intravesical mitomycin C was determined to be a significant unfavorable risk factor for late recurrence. Five patients (1.9{\%}) experienced stage progression, 3 of whom did not have metastases at the time of diagnosis of the progression but died because of bladder cancer disease. Conclusions: After a 5-year tumor-free period, even in the low-risk group, recurrence occurred at a late time point to a degree that was the same as that for the intermediate- and high-risk groups. Finally, some of the high-risk patients experienced late progression with a high degree of malignant behavior, suggesting longer follow-up is needed for each patient.",
author = "Kazuhiro Matsumoto and Eiji Kikuchi and Yutaka Horiguchi and Nobuyuki Tanaka and Akira Miyajima and Ken Nakagawa and Jun Nakashima and Mototsugu Oya",
year = "2010",
month = "6",
doi = "10.1016/j.urology.2009.09.088",
language = "English",
volume = "75",
pages = "1385--1390",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Late Recurrence and Progression in Non-muscle-invasive Bladder Cancers After 5-year Tumor-free Periods

AU - Matsumoto, Kazuhiro

AU - Kikuchi, Eiji

AU - Horiguchi, Yutaka

AU - Tanaka, Nobuyuki

AU - Miyajima, Akira

AU - Nakagawa, Ken

AU - Nakashima, Jun

AU - Oya, Mototsugu

PY - 2010/6

Y1 - 2010/6

N2 - Objectives: To evaluate the recurrence and progression in patients with non-muscle-invasive bladder tumors who remained tumor-free for at least 5 years, which should assist in the development of schedules of their follow-up evaluations. Non-muscle-invasive bladder tumors that recur or progress at a late time point are not rare. Methods: Between 1985 and 2002, 814 cases diagnosed with non-muscle-invasive bladder cancer were treated with transurethral resection. Of these 814 cases, 262 patients with no tumor recurrence for more than 5 years were included in the study. The median follow-up interval was 10.0 years. Results: During the follow-up period, 39 tumors (14.9%) showed tumor recurrence. The 5- and 10-year recurrence-free survival rates were 81.6% and 76.0%, respectively. There was no significant difference in tumor recurrence among the low-, intermediate-, and high-risk groups based on the current clinical guideline. Only the use of intravesical mitomycin C was determined to be a significant unfavorable risk factor for late recurrence. Five patients (1.9%) experienced stage progression, 3 of whom did not have metastases at the time of diagnosis of the progression but died because of bladder cancer disease. Conclusions: After a 5-year tumor-free period, even in the low-risk group, recurrence occurred at a late time point to a degree that was the same as that for the intermediate- and high-risk groups. Finally, some of the high-risk patients experienced late progression with a high degree of malignant behavior, suggesting longer follow-up is needed for each patient.

AB - Objectives: To evaluate the recurrence and progression in patients with non-muscle-invasive bladder tumors who remained tumor-free for at least 5 years, which should assist in the development of schedules of their follow-up evaluations. Non-muscle-invasive bladder tumors that recur or progress at a late time point are not rare. Methods: Between 1985 and 2002, 814 cases diagnosed with non-muscle-invasive bladder cancer were treated with transurethral resection. Of these 814 cases, 262 patients with no tumor recurrence for more than 5 years were included in the study. The median follow-up interval was 10.0 years. Results: During the follow-up period, 39 tumors (14.9%) showed tumor recurrence. The 5- and 10-year recurrence-free survival rates were 81.6% and 76.0%, respectively. There was no significant difference in tumor recurrence among the low-, intermediate-, and high-risk groups based on the current clinical guideline. Only the use of intravesical mitomycin C was determined to be a significant unfavorable risk factor for late recurrence. Five patients (1.9%) experienced stage progression, 3 of whom did not have metastases at the time of diagnosis of the progression but died because of bladder cancer disease. Conclusions: After a 5-year tumor-free period, even in the low-risk group, recurrence occurred at a late time point to a degree that was the same as that for the intermediate- and high-risk groups. Finally, some of the high-risk patients experienced late progression with a high degree of malignant behavior, suggesting longer follow-up is needed for each patient.

UR - http://www.scopus.com/inward/record.url?scp=77952742884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952742884&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2009.09.088

DO - 10.1016/j.urology.2009.09.088

M3 - Article

C2 - 20110108

AN - SCOPUS:77952742884

VL - 75

SP - 1385

EP - 1390

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -